Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 25, Issue 4, 2015, Pages 426-433

  Zhang, Y ^a   Xu, R X ^a   Li, S ^a   Zhu, C G ^a   Guo, Y L ^a   Sun, J ^a   Li, J J ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Coronary artery disease; Lipid profile; PCSK9; SdLDL; SdLDL C

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISINE KEXIN TYPE 9; SERINE PROTEINASE; SMALL DENSE LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN;

ADULT; AGE; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; AGED; BLOOD; BODY MASS; CORONARY ANGIOGRAPHY; CROSS-SECTIONAL STUDY; HOMEOSTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PARTICLE SIZE; PROCEDURES; RISK FACTOR; STATISTICAL MODEL;

AGED; ATHEROSCLEROSIS; BODY MASS INDEX; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HOMEOSTASIS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PARTICLE SIZE; PROPROTEIN CONVERTASES; RISK FACTORS; SERINE ENDOPEPTIDASES;

EID: 84933676934     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2015.01.006     Document Type: Article

References (29)

1. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239. American College of Cardiology Foundation, American Heart AssociationAmerican Heart Association.
2. Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., et al. ESC Committee for Practice guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818. European Association for Cardiovascular Prevention & Rehabilitation.
3. Berneis K.K., Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002, 43:1363-1379.
4. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group.
5. Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists' (CTT) Collaboration.
6. Hirayama S., Miida T. Small dense LDL: an emerging risk factor for cardiovascular disease. Clin Chim Acta 2012, 414:215-224.
7. Koba S., Yokota Y., Hirano T., Ito Y., Ban Y., Tsunoda F., et al. Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis. J Atheroscler Thromb 2008, 15:250-260.
8. Diffenderfer M.R., Schaefer E.J. The composition and metabolism of large and small LDL. Curr Opin Lipidol 2014, 25:221-226.
9. Abifadel M., Varret M., Rabès J.P., Allard D., Ouguerram K., Devillers M., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
10. Seidah N.G., Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012, 11:367-383.
11. Marais D.A., Blom D.J., Petrides F., Gouëffic Y., Lambert G. Proprotein convertase subtilisin/kexin type 9 inhibition. Curr Opin Lipidol 2012, 23:511-517.
12. Sun H., Samarghandi A., Zhang N., Yao Z., Xiong M., Teng B.B. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents i ts intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol 2012, 32(7):1585-1595.
13. Kosenko T., Golder M., Leblond G., Weng W., Lagace T.A. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. J Biol Chem 2013, 22(288):8279-8288.
14. Kwakernaak A.J., Lambert G., Dullaart R.P. Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins. Clin Biochem 2014, 47(7-8):679-682.
15. Feingold K.R., Moser A.H., Shigenaga J.K., Patzek S.M., Grunfeld C. Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun 2008, 374:341-344.
16. Le Bras M., Roquilly A., Deckert V., Langhi C., Feuillet F., Sébille V., et al. Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. J Clin Endocrinol Metab 2013, 98:E732-E736.
17. Li S., Guo Y.L., Xu R.X., Zhang Y., Zhu C.G., Sun J., et al. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis 2014, 234:441-445.
18. Zhang Y., Zhu C.-G., Xu R.-X., Li S., Guo Y.-L., Sun J., et al. Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. J Clin Lipidol 2014, 8:494-500.
19. Christogiannis L.G., Kostapanos M.S., Tellis C.C., Milionis H.J., Tselepis A.D., Elisaf M. Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension. J Hum Hypertens 2013, 27(1):44-50.
20. Hoefner D.M., Hodel S.D., O'Brien J.F., Branum E.L., Sun D., Meissner I., et al. Development of a rapid, quantitative method for LDL subfractionation with use of the quantimetrix lipoprint LDL system. Clin Chem 2001, 47:266-274.
21. Gentile M., Panico S., Mattiello A., Ubaldi S., Iannuzzo G., De Michele M., et al. Association between small dense LDL and early atherosclerosis in a sample of menopausal women. Clin Chim Acta 2013, 426:1-5.
22. Koba S., Hirano T., Kondo T., Shibata M., Suzuki H., Murakami M., et al. Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease. Am Heart J 2002, 144:1026-1035.
23. Hoogeveen R.C., Gaubatz J.W., Sun W., Dodge R.C., Crosby J.R., Jiang J., et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2014, 34:1069-1077.
24. Lorincz H., Katkó M., Harangi M., Somodi S., Gaál K., Fülöp P., et al. Strong correlations between circulating chemerin levels and lipoprotein subfractions in nondiabetic obese and nonobese subjects. Clin Endocrinol (Oxf) 2014, 81:370-377.
25. Ai M., Otokozawa S., Asztalos B.F., Ito Y., Nakajima K., White C.C., et al. Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem 2010, 56:967-976.
26. Li S., Guo Y.L., Xu R.X., Zhang Y., Zhu C.G., Sun J., et al. Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis. Int J Cardiol 2014, 174:863-864.
27. Werner C., Hoffmann M.M., Winkler K., Böhm M., Laufs U. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vasc Pharmacol 2014, 10.1016/j.vph.2014.03.004.
28. Rashid S., Kastelein J.J. PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia. Expert Rev Cardiovasc Ther 2013, 11:1567-1577.
29. Zheng C., Khoo C., Furtado J., Sacks F.M. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 2010, 121:1722-1734.